/Insulet%20Corporation%20phone%20and%20website-by%20T_Schneider%20via%20Shutterstock.jpg)
With a market cap of $17.2 billion, Insulet Corporation (PODD) is a leading developer and manufacturer of the Omnipod Insulin Management System, an innovative, tubeless, and easy-to-use continuous insulin delivery solution for people with insulin-dependent diabetes. It also partners with pharmaceutical and biotechnology firms to customize its Omnipod platform for the subcutaneous delivery of various drugs across different therapeutic areas.
The Acton, Massachusetts-based company is expected to release its fiscal Q1 2025 earnings results after the market closes on Thursday, May 8. Ahead of this event, analysts expect PODD to report an adjusted EPS of $0.81, up nearly 11% from $0.73 in the prior year's quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarters while missing on another occasion.